Moreover, the FAP marker PDGFRα is upregulated with TGFB1 in ALS muscle, suggesting that FAP-derived TGFB signaling is a promising therapeutic target for muscle atrophy in denervation and ALS contexts. This evidence concerns the gene PDGFRA and amyotrophic lateral sclerosis.